Diallyl disulfide (DADS), a constituent of garlic, inactivates NF-κB and prevents colitis-induced colorectal cancer by inhibiting GSK-3β

Cancer Prevention Research

Volumn 9, Issue 7, 2016, Pages 607-615

  Saud, Shakir M ^a,b   Li, Weidong ^b,c   Gray, Zane ^b   Matter, Matthias S ^d   Colburn, Nancy H ^b   Young, Matthew R ^a,b   Kim, Young S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Guang'anmen Hospital   (China)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; AZOXYMETHANE; DEXTRAN SULFATE; DIALLYL DISULFIDE; GLYCOGEN SYNTHASE KINASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ALLYL COMPOUND; ANTINEOPLASTIC AGENT; DISULFIDE; GLYCOGEN SYNTHASE KINASE 3BETA; PLANT EXTRACT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER PREVENTION; CARCINOGENESIS; CHEMOPROPHYLAXIS; COLITIS; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME INHIBITION; GARLIC; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TUMOR VOLUME; ANIMAL; CELL PROLIFERATION; CHEMICALLY INDUCED; CHEMISTRY; COLORECTAL NEOPLASMS; COMPLICATION; DRUG EFFECTS; INFLAMMATION; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ALLYL COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLITIS; COLORECTAL NEOPLASMS; DISULFIDES; GARLIC; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; INFLAMMATION; MICE; NF-KAPPA B; PLANT EXTRACTS;

EID: 84977125839     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-16-0044     Document Type: Article

References (50)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
2. JanakiramNB, Rao CV. The role of inflammation in colon cancer. Adv Exp Med Biol 2014; 816: 25-52.
3. Mariani F, Sena P, Roncucci L. Inflammatory pathways in the early steps of colorectal cancer development. World J Gastroenterol 2014; 20: 9716-31.
4. Scarpa M, Castagliuolo I, Castoro C, Pozza A, Scarpa M, Kotsafti A, et al. Inflammatory colonic carcinogenesis: A review on pathogenesis and immunosurveillance mechanisms in ulcerative colitis. World J Gastroenterol 2014; 20: 6774-85.
5. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: A meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012; 10: 639-45.
6. Kim ER, Chang DK. Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis. World J Gastroenterol 2014; 20: 9872-81.
7. Shenoy AK, Fisher RC, Butterworth EA, Pi L, Chang LJ, Appelman HD, et al. Transition from colitis to cancer: High Wnt activity sustains the tumorinitiating potential of colon cancer stem cell precursors. Cancer Res 2012; 72: 5091-100.
8. Abuajah CI, Ogbonna AC, Osuji CM. Functional components and medicinal properties of food: A review. J Food Sci Technol 2015; 52: 2522-9.
9. DiMarco-Crook C, Xiao H. Diet-based strategies for cancer chemoprevention: The role of combination regimens using dietary bioactive components. Ann Rev Food Sci Technol 2015; 6: 505-26.
10. Schafer G, Kaschula CH. The immunomodulation and anti-inflammatory effects of garlic organosulfur compounds in cancer chemoprevention. Anticancer Agents Med Chem 2014; 14: 233-40.
11. Fasolino I, Izzo AA, Clavel T, Romano B, Haller D, Borrelli F. Orally administered allyl sulfides from garlic ameliorate murine colitis. Mol Nutr Food Res 2015; 59: 434-42.
12. Erstad DJ, Cusack JC Jr. Targeting the NF-kappaB pathway in cancer therapy. Surg Oncol Clin N Am 2013; 22: 705-46.
13. Hoesel B, Schmid JA. The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer 2013; 12: 86.
14. Jing H, Lee S. NF-kappaB in cellular senescence and cancer treatment. Mol Cells 2014; 37: 189-95.
15. Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. J Int Med 2008; 263: 591-6.
16. Solt LA, May MJ. The IkappaB kinase complex: Master regulator of NFkappaB signaling. Immunol Res 2008; 42: 3-18.
17. Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NF-kappaB activation by small molecules as a therapeutic strategy. Biochimica Biophysica Acta 2010; 1799: 775-87.
18. Doble BW, Patel S, Wood GA, Kockeritz LK, Woodgett JR. Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell 2007; 12: 957-71.
19. Ghosh JC, Altieri DC. Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3beta in colorectal cancer cells. Clin Cancer Res 2005; 11: 4580-8.
20. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O,Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000; 406: 86-90.
21. Shakoori A, Mai W, Miyashita K, Yasumoto K, Takahashi Y, Ooi A, et al. Inhibition of GSK-3 beta activity attenuates proliferation of human colon cancer cells in rodents. Cancer Sci 2007; 98: 1388-93.
22. Millen AE, Subar AF, Graubard BI, Peters U, Hayes RB, Weissfeld JL, et al. Fruit and vegetable intake and prevalence of colorectal adenoma in a cancer screening trial. Am J Clin Nutr 2007; 86: 1754-64.
23. Saud SM, Young MR, Jones-Hall YL, Ileva L, Evbuomwan MO, Wise J, et al. Chemopreventive activity of plant flavonoid isorhamnetin in colorectal cancer is mediated by oncogenic Src and beta-catenin. Cancer Res 2013; 73: 5473-84.
24. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659-61.
25. Washington MK, Powell AE, Sullivan R, Sundberg JP, Wright N, Coffey RJ, et al. Pathology of rodent models of intestinal cancer: Progress report and recommendations. Gastroenterology 2013; 144: 705-17.
26. Li W, Hua B, Saud SM, Lin H, Hou W, Matter MS, et al. Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice. Mol Carcinog 2014; 54: 1096-109.
27. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 2003; 94: 965-73.
28. Young MR, Ileva LV, Bernardo M, Riffle LA, Jones YL, Kim YS, et al. Monitoring of tumor promotion and progression in a mouse model of inflammation-induced colon cancer with magnetic resonance colonography. Neoplasia 2009; 11: 237-46.
29. Kitajima S, Takuma S, Morimoto M. Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. Exp Anim 1999; 48: 137-43.
30. Karin M.Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-6.
31. Liao QJ, Su J, Zhou XT, Tang HL, Song Y, Su Q. Inhibitory effect of diallyl disulfide on proliferation of human colon cancer cell line SW480 in nude mice. Ai Zheng 2007; 26: 828-32.
32. Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknaes M, HektoenM, et al. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis 2013; 2: E71.
33. Coffey RJ Jr, Goustin AS, Soderquist AM, Shipley GD, Wolfshohl J, Carpenter G, et al. Transforming growth factor alpha and beta expression in human colon cancer lines: Implications for an autocrine model. Cancer Res 1987; 47: 4590-4.
34. Anzano MA, Rieman D, Prichett W, Bowen-Pope DF, Greig R. Growth factor production by human colon carcinoma cell lines. Cancer Res 1989; 49: 2898-904.
35. Greten FR, ArkanMC, Bollrath J, Hsu LC, Goode J, Miething C, et al.NFkappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 2007; 130: 918-31.
36. Charalambous MP, Lightfoot T, Speirs V, Horgan K, Gooderham NJ. Expression of COX-2, NF-kappaB-p65, NF-kappaB-p50 and IKKalpha in malignant and adjacent normal human colorectal tissue. Br J Cancer 2009; 101: 106-15.
37. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002; 109Suppl: S81-96.
38. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004; 18: 2195-224.
39. Demarchi F, Bertoli C, Sandy P, Schneider C. Glycogen synthase kinase- 3 beta regulates NF-kappa B1/p105 stability. J Biol Chem 2003; 278: 39583-90.
40. Wang H, Brown J, Martin M. Glycogen synthase kinase 3: A point of convergence for the host inflammatory response. Cytokine 2011; 53: 130-40.
41. Freedman VH, Shin SI. Cellular tumorigenicity in nude mice: Correlation with cell growth in semi-solid medium. Cell 1974; 3: 355-9.
42. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Intake of fat, meat, and fiber in relation to risk of colon cancer in men. Cancer Res 1994; 54: 2390-7.
43. Steinmetz KA, Kushi LH, Bostick RM, Folsom AR, Potter JD. Vegetables, fruit, and colon cancer in the Iowa Women's Health Study.AmJ Epidemiol 1994; 139: 1-15.
44. Sundaram SG, Milner JA. Diallyl disulfide suppresses the growth of human colon tumor cell xenografts in athymic nude mice. J Nutr 1996; 126: 1355-61.
45. Wargovich MJ.Diallyl sulfide, a flavor component of garlic (Allium sativum), inhibits dimethylhydrazine-induced colon cancer. Carcinogenesis 1987; 8: 487-9.
46. Gamble C, McIntosh K, Scott R,HoKH, Plevin R, Paul A. Inhibitory kappa B Kinases as targets for pharmacological regulation. Br J Pharmacol 2012; 165: 802-19.
47. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001; 293: 1495-9.
48. Heissmeyer V, Krappmann D, Wulczyn FG, Scheidereit C. NF-kappaB p105 is a target of IkappaB kinases and controls signal induction of Bcl-3-p50 complexes. EMBO J 1999; 18: 4766-78.
49. Whittle BJ, Varga C, Posa A, Molnar A, Collin M, Thiemermann C. Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3beta. Br J Pharmacol 2006; 147: 575-82.
50. Amagase H. Clarifying the real bioactive constituents of garlic. J Nutr 2006; 136: 716s-25s.